Treatment options for patients facing melanoma have dramatically expanded over the last decade. In fact, over the decade alone, 15 new therapeutic options have earned FDA approval and more than 500 clinical trials are actively enrolling patients with melanoma. Patients are living longer, better lives thanks to the power of checkpoint immunotherapies and BRAF/MEK targeted therapies.

This talk, led by Georgetown University's Dr. Michael Atkins, overviews the available treatment options for patients facing melnaoma, highlights important unanswered questions, and gives you the information you need to make informed decisions about your care.